Literature DB >> 24285772

Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.

Anna S C Conlon1, Jeremy M G Taylor, Michael R Elliott.   

Abstract

In clinical trials, a surrogate outcome variable (S) can be measured before the outcome of interest (T) and may provide early information regarding the treatment (Z) effect on T. Using the principal surrogacy framework introduced by Frangakis and Rubin (2002. Principal stratification in causal inference. Biometrics 58, 21-29), we consider an approach that has a causal interpretation and develop a Bayesian estimation strategy for surrogate validation when the joint distribution of potential surrogate and outcome measures is multivariate normal. From the joint conditional distribution of the potential outcomes of T, given the potential outcomes of S, we propose surrogacy validation measures from this model. As the model is not fully identifiable from the data, we propose some reasonable prior distributions and assumptions that can be placed on weakly identified parameters to aid in estimation. We explore the relationship between our surrogacy measures and the surrogacy measures proposed by Prentice (1989. Surrogate endpoints in clinical trials: definition and operational criteria. Statistics in Medicine 8, 431-440). The method is applied to data from a macular degeneration study and an ovarian cancer study.

Entities:  

Keywords:  Bayesian estimation; Principal stratification; Surrogate endpoints

Mesh:

Substances:

Year:  2013        PMID: 24285772      PMCID: PMC4023321          DOI: 10.1093/biostatistics/kxt051

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  16 in total

1.  Principal stratification in causal inference.

Authors:  Constantine E Frangakis; Donald B Rubin
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

2.  The validation of surrogate endpoints in meta-analyses of randomized experiments.

Authors:  M Buyse; G Molenberghs; T Burzykowski; D Renard; H Geys
Journal:  Biostatistics       Date:  2000-03       Impact factor: 5.899

3.  Evaluating correlation-based metric for surrogate marker qualification within a causal correlation framework.

Authors:  Yue Wang; Robin Mogg; Jared Lunceford
Journal:  Biometrics       Date:  2011-11-07       Impact factor: 2.571

4.  Bayesian inference for partially identified models.

Authors:  Paul Gustafson
Journal:  Int J Biostat       Date:  2010       Impact factor: 0.968

5.  ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.

Authors:  Li Qin; Peter B Gilbert; Dean Follmann; Dongfeng Li
Journal:  Ann Appl Stat       Date:  2008-03       Impact factor: 2.083

6.  Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'.

Authors:  Peter B Gilbert; Li Qin; Steven G Self
Journal:  Stat Med       Date:  2009-02-15       Impact factor: 2.373

7.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

8.  A Bayesian approach to improved estimation of causal effect predictiveness for a principal surrogate endpoint.

Authors:  Corwin M Zigler; Thomas R Belin
Journal:  Biometrics       Date:  2012-02-20       Impact factor: 2.571

9.  Surrogate measures and consistent surrogates.

Authors:  Tyler J Vanderweele
Journal:  Biometrics       Date:  2013-09       Impact factor: 2.571

10.  End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Authors:  Daniel J Sargent; Smitha Patiyil; Greg Yothers; Daniel G Haller; Richard Gray; Jacqueline Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; David Kerr; Erin Green; Harry S Wieand; Richard M Goldberg; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2007-09-17       Impact factor: 44.544

View more
  15 in total

1.  Augmented trial designs for evaluation of principal surrogates.

Authors:  Erin E Gabriel; Dean Follmann
Journal:  Biostatistics       Date:  2016-01-28       Impact factor: 5.899

2.  Evaluating surrogate marker information using censored data.

Authors:  Layla Parast; Tianxi Cai; Lu Tian
Journal:  Stat Med       Date:  2017-01-15       Impact factor: 2.373

3.  Assessing the value of a censored surrogate outcome.

Authors:  Layla Parast; Lu Tian; Tianxi Cai
Journal:  Lifetime Data Anal       Date:  2019-04-12       Impact factor: 1.588

4.  Using a surrogate marker for early testing of a treatment effect.

Authors:  Layla Parast; Tianxi Cai; Lu Tian
Journal:  Biometrics       Date:  2019-04-22       Impact factor: 2.571

5.  Surrogacy assessment using principal stratification with multivariate normal and Gaussian copula models.

Authors:  Jeremy M G Taylor; Anna S C Conlon; Michael R Elliott
Journal:  Clin Trials       Date:  2014-12-09       Impact factor: 2.486

6.  Surrogacy assessment using principal stratification and a Gaussian copula model.

Authors:  Asc Conlon; Jmg Taylor; M R Elliott
Journal:  Stat Methods Med Res       Date:  2016-07-11       Impact factor: 3.021

7.  Links between causal effects and causal association for surrogacy evaluation in a gaussian setting.

Authors:  Anna Conlon; Jeremy Taylor; Yun Li; Karla Diaz-Ordaz; Michael Elliott
Journal:  Stat Med       Date:  2017-08-08       Impact factor: 2.373

8.  Quantifying the feasibility of shortening clinical trial duration using surrogate markers.

Authors:  Xuan Wang; Tianxi Cai; Lu Tian; Florence Bourgeois; Layla Parast
Journal:  Stat Med       Date:  2021-09-02       Impact factor: 2.373

9.  Evaluating multiple surrogate markers with censored data.

Authors:  Layla Parast; Tianxi Cai; Lu Tian
Journal:  Biometrics       Date:  2020-09-22       Impact factor: 2.571

10.  Robust methods to correct for measurement error when evaluating a surrogate marker.

Authors:  Layla Parast; Tanya P Garcia; Ross L Prentice; Raymond J Carroll
Journal:  Biometrics       Date:  2020-10-16       Impact factor: 1.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.